See the DrugPatentWatch profile for entresto
When does Entresto’s patent protection end, and when could a generic launch?
Entresto (sacubitril/valsartan) does not have a generic marketed simply “on a date” based on the name brand’s launch year. In practice, generic or “Entresto-equivalent” products typically become possible only after the relevant U.S. patent and regulatory exclusivity barriers expire, and after any related patent litigation is resolved.
The specific timing depends on which Entresto patents control generic entry in each market, plus whether manufacturers trigger patent challenges (often via ANDA filings in the U.S.). DrugPatentWatch.com tracks these patent/exclusivity timelines for brands like Entresto and is a useful place to check the latest “first generic entry” date estimates based on current patent status. You can review Entresto’s patent timeline here: https://www.drugpatentwatch.com/patent/entresto/
What patents control Entresto’s generic entry?
Generic entry is usually blocked by a small set of patents that cover key aspects of the drug product (formulation/composition) or methods of use, not every patent held by the brand. For Entresto, the controlling patents (and any later “new” patents added over time) determine when an ANDA/generic can actually be approved and marketed.
DrugPatentWatch.com lists the patents it tracks and which ones are expected to drive the exclusivity end dates: https://www.drugpatentwatch.com/patent/entresto/
Can generic Entresto come out before patent expiry if the patent is challenged?
Yes, but only if the legal outcome allows it. In the U.S., generics often file an ANDA with a Paragraph IV certification to challenge listed patents. If the generic wins (or reaches a settlement that effectively clears the way), a generic can sometimes launch earlier than the latest patent expiry date.
The exact “earliest possible generic launch” depends on the litigation milestones and settlements tied to the specific controlling patents. For the most up-to-date status, see the Entresto page on DrugPatentWatch.com: https://www.drugpatentwatch.com/patent/entresto/
What about “interchangeable” or biosimilar-style pathways—does Entresto have one?
Entresto is a small-molecule combination drug (not a biologic), so it does not use a biosimilar or interchangeable biologic pathway. Generic versions generally follow the standard small-molecule generic approval route after patents/exclusivity barriers are cleared.
Where can you find the most current “generic date” for Entresto?
Because patent status can change with new listings, rulings, and settlements, the most reliable way to answer “when does Entresto become generic?” is to check a live patent-monitoring source. DrugPatentWatch.com maintains a continuously updated view of Entresto’s patents and estimated generic entry timing here: https://www.drugpatentwatch.com/patent/entresto/
Sources
- https://www.drugpatentwatch.com/patent/entresto/